

US008066768B2

(12) United States Patent

Werblin

(10) Patent No.:

US 8,066,768 B2

(45) Date of Patent:

Nov. 29, 2011

INTRAOCULAR LENS SYSTEM

Theodore P. Werblin, Princeton, WV Inventor:

(US)

Werblin Research & Development (73)

Corp., Princeton, WV (US)

Subject to any disclaimer, the term of this Notice:

patent is extended or adjusted under 35

U.S.C. 154(b) by 398 days.

Appl. No.: 11/698,875 (21)

Jan. 29, 2007 (22)Filed:

(65)**Prior Publication Data**

US 2008/0183289 A1 Jul. 31, 2008

(51)Int. Cl.

A61F 2/16 (2006.01)

(52)

(58)623/6.34, 6.57, 6.32, 6.44

See application file for complete search history.

References Cited (56)

U.S. PATENT DOCUMENTS

2,036,379	\mathbf{A}	4/1936	Woodward
2,039,144	A	4/1936	Burgess
2,168,925	A	8/1939	Hewes
2,354,586	A	7/1944	Fischer
2,798,373	A	7/1957	Harza
2,806,809	A	9/1957	Schuh
3,128,576	A	4/1964	Bradley
3,194,130	A	7/1965	Guntert
3,200,482	A	8/1965	Brown
3,265,556	A	8/1966	Hungerford
3,269,282	A	8/1966	Beesley et al.
3,458,870	A	8/1969	Stone, Jr.
3,945,054	A	3/1976	Fedorov et al.
/ /		3/1977	
4,240,163	A	* 12/1980	Galin 623/6.57

4,373,218 A	2/1983	Schacher				
4,402,579 A	9/1983	Poler				
4,575,373 A	3/1986	Johnson				
4,585,456 A	4/1986	Blackmore				
4,585,457 A	4/1986	Kalb				
4,636,212 A	1/1987	Posin et al.				
4,655,770 A	4/1987	Gupta et al.				
4,685,921 A	8/1987	Peyman				
4,685,922 A *	8/1987	Peyman	623/6.13			
4,731,078 A	3/1988	Stoy et al.				
(Continued)						

FOREIGN PATENT DOCUMENTS

DE 707212 5/1941

(Continued)

OTHER PUBLICATIONS

Werblin et al., "Epikeratophakia: The surgical correction of aphakia. III. Preliminary results of a prospective clinical trial," 93 Arch. Opth., pp. 342-347 (1982).


(Continued)

Primary Examiner — David H Willse Assistant Examiner — Tiffany Shipmon (74) Attorney, Agent, or Firm — Arent Fox LLP


(57)**ABSTRACT**


A multi-component intraocular lens implanted in an optical system of a human eye includes one or more removable components, each component being foldable. One component acts as a base lens, including a flange with an aperture. Another component acts as a mid lens, including a tab which engages the aperture. A third component acts as a top lens, which engages the mid lens. Because the lens components are foldable, they may be inserted into the eye using an incision smaller than the diameter of the unfolded lens. The removable components may be used to correct various medical conditions of the eye, as well as to improve and enhance vision, and for cosmetic purposes.


22 Claims, 13 Drawing Sheets




	a b				TD 0.405.505.D4 0.44005		
	U.S. P.	ATENT	DOCUMENTS		EP 0 435 525 B1 3/1995		
4,769,035	A	9/1988	Kelman		FR 2666735 3/1992		
4,778,463			Hetland		WO WO 91/06259 A1 5/1991		
4,787,903			Grendahl		WO WO 9220302 11/1992		
4,834,754			Shearing				
4,838,266			Koziol et al.		OTHER PUBLICATIONS		
4,842,601			Smith	623/6.34	OTTILITY ODDITIONS		
4,863,466			Schlegel		Werblin et al., "Hydrogel Keratophakia: Measurement of Intraocular		
4,892,543		1/1990	e	025, 0	Pressure," vol. 11, No. 4 CLAO Journal, pp. 354-357 (Oct. 1985).		
4,932,971			Kelman	623/6.34			
4,950,289			Krasner	025, 0.5 1	Werblin et al. "Refractive Corneal Surgery: The Use of Implantable		
5,066,301		11/1991			Alloplastic Lens Material," 11 Austrial Journal of Opthalmology, pp.		
5,085,013			Ascosi et al	451/460	325-331 (1983).		
5,098,444		3/1992		1517 100	Werblin "Lamellar Refractive Surgery: Where Have We Been and		
5,133,748			Feaster	623/6 12			
5,171,267			Ratner et al.	025,0.12	Where are we going?" vol. 5, No. 3, Refractive and Corneal Surgery,		
5,196,027			Thompson et al.		pp. 167-176 (Jan. 1989).		
5,222,981	_		Werblin	623/6 34	Binder et al. "Hydrogel Refractive Keratoplasty. Lens Removal and		
5,288,293			O'Donnell, Jr.	025,0.51	Exchanges" vol. 2, Cornea at pp. 119-125.		
5,366,502		11/1994			Wikipedia, "Presbyopia", The Free Encyclopedia, pp. 1-4, Oct. 30,		
5,628,798			Eggleston et al	623/6 11			
5,728,155			Anello et al.	025/0.11	2006.		
5,777,719			Williams et al.		Ernani Serpa Junior, et al., "Comparison of PMMA, foldable silicone		
5,814,103			Lipshitz et al	623/6 34	and foldable acrylic hydrophobic intraocular lenses in combined		
5,892,617			Wallace	025,0.51	phacoemulsification and trabeculectomy", Arq Bras Oftalmol. 2005;		
5,943,117			Van de Velde		68 (1):29-35.		
5,968,094			Werblin et al	623/6 34			
6,113,633			Portney		Cyw Khng, et al., "The IOL flip: rescue for foldable lens implantation		
6,254,637			Lee et al.		gone wrong", The BMJ Interview—BJO Online Journals, Oct. 30,		
6,255,338			Duncan et al.	023,3.11	2006, pp. 1-5.		
6,413,276			Werblin		Cyw Khng, et al., "The IOL flip: rescue for foldable lens implantation		
6,524,340			Israel		gone wrong", BJO Online Journals, Br. J. Ophthalmol 2003;87;656-		
6,551,354	_		Ghazizadeh et al		657 doi:10.1136/bjo.87.5.656.		
6,991,651	_		Portney				
7,008,449			Willis et al.	025,0.5	Theodore P. Werblin, "Why Should Refractive Surgeons Be Looking		
7,097,660			Portney	623/6.22	Beyond the Corenea?", Barraquer Lecture 1998, Journal of Refrac-		
/ /			Tran		tive Surgery vol. 15 May/Jun. 1999, pp. 359-376.		
2002/0161436			Portney		Werblin et al., "Epikeratophakia: The surgical correction of aphakia.		
			Peng et al		III. Preliminary results of a prospective clinical trial," 99 Arch. Opth.,		
2005/0125058			Cumming et al		pp. 1957-1960 (1981).		
			Brown		Werblin et al., Epikeratophakia: The surgical correction of aphakia.		
Weronn et al., Lpikeratophakia. The surgical confection							
FC	REIGI	N PATEI	NT DOCUMENTS	II. Preliminary results in a non-human primate model; 1(3) Curr. Eye			
ÞΕ	2/128	895 A1	2/1986		Res., pp. 131-137; 1981.		
EP		198 A1	6/1988		* cited by examiner		
1	0 209	170 A1	0/1700		ched by examine		












FIG.6 (RELATED ART)




FIG.7
(RELATED ART)





FIG.8 (RELATED ART)

FIG.9 (RELATED ART)











FIG. 11 (RELATED ART)

















INTRAOCULAR LENS SYSTEM

BACKGROUND OF THE INVENTION

1. Field of the Invention

This invention relates to a method for correcting the optical system of an eye using an intraocular lens system. Particularly, this invention relates to a method of correcting focusing abnormalities and optical aberrations measured by wave front or similar technology to quantify optical aberrations in the optical system of the eye, using a laser, or other apparatus and/or methods of fabricating or modifying a lens, for the optical system of an eye having a foldable, interchangeable intraocular lens system provided therein.

2. Description of Related Art

The field of refractive surgery has evolved rapidly during the past few decades. Current procedures and methods used by refractive surgeons may not satisfy the total refractive needs of the patient. Particularly, the most commonly performed refractive surgical procedures, such as, for example, 20 cataract extraction with intraocular lens implantation, in addition to the most recently popularized corneal refractive surgical procedures, such as eximer laser photoblation, exhibit limitations. One reason for the limitations is the lack of postoperative refractive accuracy. The lack of post-operative 25 refractive accuracy renders the commonly known refractive surgical procedures uncompetitive with currently available non-surgical alternatives for patients, for example, glasses and contact lenses. Further, because refractive surgery requires local or general anesthesia and incisions into the eye, 30 a need exists for decreasing the trauma resultant from the surgery.

Recently, a need has arisen for efficient treatment of presbyopia, or the diminished power of accommodation of the eye. Presbyopia is a condition which typically affects a large 35 number of people as they age, with the severity of the condition varying depending on the person. Difficulties arise in treating presbyopia because typically once a person manifests symptoms of presbyopia, the symptoms worsen as the person ages. As a person's condition worsens, a different, usually 40 more powerful, lens is required to correct the condition. Conventional techniques for replacing an intraocular lens each time the patient's vision deteriorated do not always present a practical or cost-effective approach. Recent developments in the field, of refractive surgery have made intraocular treat- 45 ment of presbyopia a feasible course of treatment for those patients that desire or need improved vision, however a need exists for more precise techniques and devices for use in refractive intraocular surgery.

Patients suffering from eye trauma or other eye afflictions 50 may have the iris or other portions of the eye distorted, destroyed, or discolored. Currently, such patients are typically prescribed cosmetic contact lenses. Cosmetic intraocular lens replacement is emerging as a viable alternative, however a need exists for more efficient intraocular lens 55 replacement in order to minimize eye trauma and establish cosmetic intraocular lens replacement as a safe and effective alternative to cosmetic contact lenses and other nonsurgical treatments. As surgical techniques become more effective, safer, and less painful, patients may choose to have elective 60 lens replacement surgery to change the color, structure, or shape of their eyes. By providing a minimally invasive method for lens replacement as described in an embodiment herein, the surgeon is able to limit the drawbacks of the procedure.

Current procedures and methods for refractive surgery require the performing surgeon to execute the procedure with

2

a high level of skill and experience. Currently, methods and procedures for carrying out refractive surgery involving intraocular lenses generally require direct visualization of the intraocular lens assembly within the eye. Such visualization, although not outside the scope of a surgeon skilled in the art, increases the degree of difficulty of the procedure, thus increasing the chance that a surgical error or other problem will arise in the surgical procedure, leading to unwanted complications. Thus, a need exists for intraocular lens assemblies and systems whose structures provide less complex methods of insertion into and extraction from the eye.

Currently, refractive cataract surgeons performing the most common refractive surgical procedure, i.e., routine cataract surgery, obtain refractive accuracies in a +/-0.75 to +/-1.00 diopter (D) range. However, the industry has established goals of obtaining refractive accuracies in the +/-0.25 D range. Therefore, there is a need in the industry to provide a more accurate alternative to the current procedure. Furthermore, analyses of current corneal refractive technologies indicate the presence of a significant amount of preexisting or naturally occurring post-operative, as well as preoperative, image distortion (optical aberration) or degradation, particularly under low light conditions, such as when driving at night.

Due to the practical limits of performing intraocular surgery, as well as the biological and physical behavior of the human eye during and after various types of intraocular surgery, predictability at the +/-0.25 D accuracy level with-a single surgical procedure is difficult to achieve as a practical matter. Furthermore, factors such as biometry errors, variable wound healing, and capsular contraction around the intraocular lenses contribute to decreasing the likelihood of achieving the desired refractive accuracy. Accordingly, practitioners in the industry have found that an adjustable intraocular lens (IOL), hereinafter referred to as the MC-IOL (multi-component) or C-IOL (compound), following lens extraction surgery provides a plurality of desirable options for refractive surgeons and patients.

An adjustable IOL allows fine tuning of the initial refractive result by exchanging at least one of the optical elements of the lens implant. As a result, accuracies in the +/-0.25 D range are readily attainable. Furthermore, patients are provided with an opportunity to exchange the "old" lens components with new and hopefully more accurate components. Such an objective is obtainable if the surgeon has an effective, efficient, and safe method of performing lens element exchanges. Additionally, months and/or years after the refractive surgical procedure, if the optical properties of the inserted IOL, for example, the multifocality, become problematic, the surgeon should have the ability to safely exchange the undesirable optical elements of the IOL to correct any optical aberrations that the patient will not or cannot tolerate.

In 1990, the inventor of this application developed a multi-component intraocular lens, hereinafter referred to as the MC-IOL (FIG. 1), for use following clear lens or refractive cataract surgery, wherein the optical properties of the MC-IOL can be modified at any post-operative time. The base intraocular lens component of the MC-IOL is shown in FIG. 1. The mid lens attaches to the top of the base lens and holds the third component of the MC-IOL, the top lens, in place.

The base intraocular lens 10 and the mid lens 20 each have securing flanges 16, 18 and 20, 24, respectively, extending therefrom. The MC-IOL also comprises at least one top lens 30, as illustrated in FIG. 1. The top lens 30 is positioned on top of the mid lens 20. See FIGS. 1-2.

The MC-IOL also includes projections (or haptics) 11 and 13 which securely hold the MC-IOL in the tissue of the human eye. The above-described

structure permits the base intraocular lens 10 to form a platform upon which the mid lens 20 is placed, and to hold the 5 top lens 30. During routine cataract surgery, the MC-IOL replaces the crystalline lens of the human eye. Once a patient's eye has healed after such a surgery, the surgeon reenters the eye and replaces, if necessary, and more than once, the top lens 30 and the mid lens 20 to modify the optical 10 characteristics of the eye until the desired levels for each optical characteristic are attained.

FIGS. 3A-3B illustrate an assembled compound intraocular lens, hereinafter C-IOL, used with a preexisting lens lar to the mid lens (FIGS. 4A-4B) and the top lens (FIGS. **5**A-**5**B) components of the MC-IOL. FIG. **5** also illustrates the axis orientation mark 85 used in some embodiments of MC-IOL lenses, to aid in positioning and orienting the lens. The preexisting lens can be the crystalline lens of the eye with 20 the C-IOL placed in the sulcus (FIG. 6) or in the anterior chamber angle (FIG. 7) of the eye's optical system. However, the C-IOL can also be used with a conventional IOL, as well as with an accommodating IOL, and mounted in the sulcus (FIG. 8), in the anterior chamber angle (FIG. 9), in the ante- 25 rior chamber with posterior chamber fixation (FIG. 10) or in the anterior chamber with iris fixation (FIG. 11). Thus, a surgeon modifies the optical characteristics of the optical system of the eye by using the mid and top lenses in tandem with the preexisting conventional IOL implant or crystalline 30 lens of the eye.

The C-IOL and MC-IOL provide numerous enhanced features. For example, the C-IOL and MC-IOL can each be structured as a monofocal or multifocal optical system, correct astigmatism, as well as comprise ultraviolet light-absorb- 35 ing, tinted, or other such chemically treated materials.

It should be understood that there are various reasons why an adjustable MC-IOL or C-IOL is more desirable than a single component implant. In order to achieve all the permutations and combinations of the astigmatism, multifocality, 40 and spherical correction needed to achieve emmetropia would take an inventory of over ten thousand lenses, whereas with the MC-IOL (multiple components) concept, an inventory of about one hundred components would be necessary. With anterior chamber lenses, progressive encapsulation or 45 engulfment of the lens haptics by uveal tissue in the angle often occurs 1-2 years post-operatively. The engulfment typically makes the removal of the lenses and their haptics more difficult. Exchange of iris fixated anterior chamber lenses does not typically guarantee precise position or orientation. 50 Posterior chamber lenses similarly cannot be removed because of posterior capsule fibrosis. Easy removal and exchangeability is critical for any customized emmetropic system, which can be provided by a specially designed multicomponent lens system.

Therefore, based on the above, a MC-IOL having three elements rather than one permits refractive customization and adjustability for all refractive errors, as well as for all patients, while using a minimal number of lens elements or parts and requiring little customization on the part of the manufacturer. 60 Thus, it has become very important in the refractive surgery art to be able to individualize and/or customize surgery such that the surgeon can easily and safely, as well as accurately, modify the refractive power of an intraocular lens implant.

For example, U.S. Pat. No. 5,288,293 to O'Donnell, Jr. 65 discloses a method of modifying a single IOL. O'Donnell suggests that the refractive power of a single IOL may be

varied before implantation so that the changes can be made in situ by the ophthalmologist after determining the extent of correction required to improve the vision of the patient before the lens is made. However, the surgical implantation procedure itself may create additional optical aberrations which cannot be anticipated preoperatively and thus the primary lens implant cannot account for these optical aberrations.

As such, it may be argued that if a lens can be modified before being implanted, as suggested by O'Donnell, Jr., it should be possible to modify the implanted lens by removing the implanted lens, modifying the lens, and then reimplanting the modified lens into the optical system of the eye. However, the design of current intraocular lenses typically makes such a procedure difficult and impractical. Furthermore, after a within the human eye. The C-IOL has two components simi- 15 period of time with normal healing, it becomes physically dangerous and/or nearly impossible to the patient to have the implanted lens removed once the eye tissue takes hold on the capsular fixation holes of the lens. Therefore, such an argument is not realistic, practical, or safe. A single component intraocular lens, which in general is not designed to be removed and with only two optical surfaces, cannot accurately allow for compensation of sphere, cylinder, cylindrical axis, and all forms of optical aberrations that may be discovered after the initial implantation. However, the MC-IOL typically will have four removable optical surfaces which can compensate for these optical properties.

The inventor of this application invented the previously discussed MC-IOL and C-IOL that are designed specifically to permit the easy exchange of optical elements at a postoperative period without risk to the human eye or to the patient, beyond the risk of ordinary intraocular surgery. The easy exchangeability of optical elements is critical because the actual surgery of implanting the lens in the first place, as well as variances in the manner in which the eye heals after implantation, potentially create distortions which may not stabilize for several months after the operation. Therefore, the ability to measure and to compensate for the distortion(s) optimally takes place several months after surgery and cannot typically be predicted prior thereto. Since the same surgical wound is used for both the primary and secondary operations, additional distortion due to wound healing would not be anticipated as a result of the second operation.

Furthermore, the ability to exchange optical elements of a multicomponent or compound intraocular lens can be economical compared to removing, modifying, and re-implanting a single component lens, as well as easier to perform.

The MC-IOL has four surfaces available for modification, two piano and two convex. Preferably, the modification is made only to the piano surfaces to avoid interfering with the convex side which may already be used for correction of astigmatism (cylinder) or used as a multifocal lens surface. The same preference applies to the CIOL, which has two surfaces available for modification, one piano and the other convex.

The inventor of this application also developed a system for correcting optical aberrations in the MC-IOL, as described, for example, in U.S. Pat. No. 6,413,276, for conducting measurements to determine any residual or new aberrations present in an operated eye after the biological healing parameters have stabilized, as well as to correct any errors in sphere, cylinder, or cylindrical axis, and for modifying one, two, or more existing lens elements within the implanted optical system based on the conducted measurements.

In conventional multi-component intraocular lens designs, the surgical procedure required to implant the intraocular lens components requires a high level of surgeon skill. For example, implantation of the removable component of the

lens requires the surgeon to directly visualize the placement of the lens in order to match the notches with the flanges. Further, removal of the removable lens component requires a special forceps tool for grabbing the base lens, and releasing the tabs holding the sandwich and cap lens together with the base lens (see, for example, the system described in U.S. Pat. No. 5,968,094).

Historically intraocular lens systems used a rigid one piece poly methyl methacrylate (PMMA) lens. The PMMA lens is approximately six millimeters in diameter. Because the 10 PMMA lens is rigid, insertion of the PMMA intraocular lens generally requires a seven or eight millimeter incision to be inserted into the eye. In contrast, a flexible or foldable lens can be manipulated and compacted to a much smaller size. Once compacted, the multi-component intraocular lens can be 15 delivered using a relatively smaller incision, for example, about three millimeters or less. By using a smaller incision, the patient reaps optical and practical benefits. From an optical standpoint, any time incisions are made to the cornea, the cornea loses some of its natural globularity due to imperfec- 20 tions caused by the incisions and the resultant trauma. The imperfections in the cornea lead to induced astigmatism, or optical aberrations caused by irregularities in the shape of the cornea. By minimizing the size of the corneal incision, a surgeon may also minimize the amount of induced astigma- 25 tism. Even though the three-component design simplifies the process of correcting induced astigmatism, minimizing the amount of induced astigmatism remains a primary goal for all intraocular surgeries.

As a practical matter, by making a smaller incision, the surgeon reduces the amount of actual trauma to the eye, thus reducing the occurrence of complications and decreasing the time for recovery. These advantages are further realized if the surgeon is able to perform the intraocular surgery using an incision small enough to heal without the use of stitches, wherein the incision is small enough to allow the eye's natural ocular pressure to hold the incision together during the healing process.

SUMMARY OF THE INVENTION

It is an aspect of this invention to overcome the above-described drawbacks of the related art.

In particular, it is an aspect of this invention to provide a multi-component intraocular lens system with components 45 that are removable after placement in the eye. It is an additional aspect of the present invention to provide a multi-component intraocular lens system with foldable components in order to minimize trauma to the eye. Trauma is minimized by allowing the use of a delivery system for the foldable lens 50 which requires an incision smaller than the unfolded diameter of the foldable lens.

It is a further aspect of this invention to provide a multi-component intrabcular lens system with components designed to simplify the surgical procedure for intraocular 55 lens component insertion. An embodiment of the present invention includes a multi-component intraocular lens, wherein the base lens is attached with haptics, and the top and mid lenses are assembled outside the eye. The top and mid lenses may include projections designed to lock into place 60 with flanges of the base lens. The intraocular lens system allows assembly without the use of special equipment or techniques for securing the top and mid lenses to the base lens. The intraocular lens system also does not require that the surgeon performing the operation be able to see or visualize 65 the insertion of the top and mid lenses. Rather, in the present invention, the surgeon merely slides the folded mid/top lens

6

assembly into the eye, unfolds the assembly in the eye, and slides the assembly across the base lens component until each projection aligns with a corresponding flange.

It is an aspect of the present invention to provide a modified multi-component intraocular lens implanted in an optical system of a human eye, including three or more removable components, with each component being foldable, and two of the removable components being connected to each other by a flange and slot.

It is a further aspect of the present invention to provide a multi-component intraocular lens for an eye, including a foldable base intraocular lens component, a foldable removable lens component, and a foldable mid intraocular lens component. The foldable removable lens component is attached to the foldable mid intraocular lens component by a notch along the circumference of the foldable removable lens component.

It is yet another aspect of the present invention to provide a system for the administration of pharmacological agents through an intraocular lens system capable of the time-delayed release of medicine into the eye over a predetermined, and/or adjustable period of time.

The use of an adjustable intraocular lens allows adjustment or exchange of optical elements, both spherical and cylindrical, independent of any additional wound healing or significant calculation error to fine-tune, reverse, or replace any of the original optical features.

BRIEF DESCRIPTION OF THE FIGURES

In the drawings:

FIG. 1 is a plan view of the base, mid, and top lens components of a currently known multi-component intraocular rigid lens;

FIG. 2 is an exploded side view of the assembled base, top, and mid lenses of the currently known multi-component intraocular rigid lens shown in FIG. 1;

FIGS. 3A-3B are exploded views of a two component compound intraocular lens;

FIGS. 4A-4B are top and side views, respectively, of a type of compound intraocular lens-top lens component;

FIGS. **5**A-**5**B are top and side views, respectively, of a type of compound intraocular lens-top lens component;

FIG. 6 is a side view of a compound intraocular lens implanted within a human eye ciliary sulcus;

FIG. 7 is a side view of another compound intraocular lens implanted within a human eye using the anterior chamber angle as support;

FIG. **8** is a side view of a sulcus mounted compound intraocular lens implanted within a human eye with a previously implanted single component conventional intraocular lens mounted in the capsular bag;

FIG. 9 is a side view of an anterior chamber mounted compound intraocular lens implanted within a human eye with a previously implanted single component conventional intraocular lens mounted in the capsular bag;

FIG. 10 is a side view of an anterior chamber mounted compound intraocular lens on a support secured in the posterior chamber and is implanted within a human eye with a previously implanted single component conventional intraocular lens mounted in the capsular bag;

FIG. 11 is a side view of an iris fixated compound intraocular lens in the anterior chamber that is implanted within a human eye with a previously implanted single component conventional intraocular lens mounted in the capsular bag;

FIG. 12 is a top view, with an enlarged side view cutaway, of the base component of a foldable multi-component intraocular lens according to an embodiment of the present invention;

FIG. 13 is a top view of the base component of a foldable 5 multi-component intraocular lens according to another embodiment of the present invention;

FIGS. 14A and 14B are an exploded top view and an exploded side view, respectively, of the mid lens replaceable component of a foldable multi-component intraocular lens according to an embodiment of the present invention;

FIG. 15 is an exploded top view of the top lens component of a foldable multi-component intraocular lens according to an embodiment of the present invention; and

FIG. **16** is a side view of the inventive assembly when the top lens is inserted into the mid lens according to an embodiment of the present invention.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

FIG. 12 shows a top or plan view of the intraocular foldable base lens 100 in a preferred embodiment of the present invention. The base lens 100 is similar to the MC-IOL base lens illustrated in FIG. 3. The base lens 100 is preferably manufactured from acrylic or silicone materials, but the base lens 100 can be manufactured from any suitable foldable material. The base lens 100 has a diameter ranging from 1.00 to 8.00 millimeters, but preferably is between 5.50 and 6.50 millimeters, and has an optical aperture ranging from 3.0 millimeters 30 to 7.0 millimeters, with a preferable optical aperture of 5.5 millimeters.

As mentioned above, the base lens 100 has a diameter ranging from 1.00 to 8.00 millimeters, and is preferably composed of foldable material. Accordingly, the insertion of the 35 base lens 100 into the eye requires an incision therein which is less than half as large as the diameter of the base lens 100.

The base lens 100 attaches to the eye by at least one haptic 120. In FIG. 12, the base lens 100 is secured to the eye by at least one, but preferably two haptics 120, however, this is 40 merely one embodiment of the present invention, and other embodiments may use one or more haptics 120 to secure the base lens 100 to the eye.

The haptics **120** illustrated in FIG. **12** have a span ranging from 5.0 millimeters to 15.0 millimeters. In a system where 45 the base lens **100** has two haptics extending outward, the two haptics each have a preferable span of 12.0 to **13**.0 millimeters. The preferable length of the haptics **120** depends on the number of haptics extending from the base lens **100**. Each haptic **120** extends outward from the base lens **100**, and is 50 tilted from between 10 to 20 degrees, in either direction, relative to a plane taken across the base lens, preferably having a 15 degree positive tilt.

The base lens 100 includes one or more flanges 105 disposed on and extending outwardly away from the body of the base lens 100, preferably forming a perpendicular angle with the plane of the base lens, however the flanges 105 could extend outward from the body of the base lens at any angle from 45 degrees to 135 degrees. In a preferred embodiment, such as the embodiment illustrated in FIG. 12, two flanges 105 are disposed on either side of the base lens 100. However, the invention is not limited to this embodiment, as more flanges 105 may be disposed in various locations around the base lens 100.

Each flange 105 has a slot 110 designed or configured to 65 receive or accept an assembly of a top lens 300 and a mid lens 200 therein, which will be described in more detail herein.

8

The slot 110 illustrated in FIG. 12 is in the shape of a parallelogram, however other shaped slots, such as elliptical, oval, trapezoidal, rounded rectangular, or any other known geometric shape are considered to be within the scope and pervue of the present invention.

The base lens incorporated into another embodiment of the present invention is illustrated in FIG. 13. The base lens 102 is similar to the base lens 100, except for a groove 130 defined in the base lens 100 and extending along the entire outer periphery of the base lens 102, and four attachment points 140, which serve to attach the optical region 150 to the base lens 102. Although four attachment points 140 are illustrated here, embodiments with more attachment points or fewer attachment points are also considered to be within the scope and pervue of the invention. In all other aspects, the base lens 102 is the same as the base lens 100 illustrated in FIG. 12.

In an embodiment of the present invention, the base lens 100 is infused with chromophores, which absorb light in a portion of the light spectrum. For example, the base lens could be infused with chromophores to absorb light from the ultraviolet wavelength portion of the light spectrum, typically between 380 and 389 nm. By absorbing light in the ultraviolet wavelength portion of the spectrum, the intraocular lens system reduces eye glare, enhances vision capabilities, and helps protect the eye from potentially harmful ultraviolet rays. Although ultraviolet light is exemplified here, other color chromophores, which are used to block other wavelengths of light, are also considered within the scope and pervue of the invention.

The foldable MC-IOL includes two or more additional refractive components, including an assembly of the top lens 300 and the mid lens 200, described more fully herein. One embodiment of the mid lens 200, hereinafter interchangeably referred to as the "middle" lens, the "cap" lens, or the "removable component" lens, is illustrated in FIGS. 14A and 14B. The mid lens 200 allows spherical adjustments from –4.00 D to +4.00 D in 0.25 D increments. In an embodiment of the present invention, the top lens 300 carries the astigmatic correction, which can range, for example, from 0.00 D to 5.00 D cylinder in 0.25 D increments and has an orientation projection 305. The present values are presented merely for illustrative purposes, and other possible ranges for the cylinder at various sphere values are considered to be within the scope and pervue of the invention.

Like the base lens 100, the top lens 300 may be constructed from acrylic, silicone, or any other material suitable for manufacturing a foldable intraocular lens. The top lens 300 has a central thickness ranging from 0.1 millimeters to 0.4 millimeters, and a diameter ranging from 1.50 to 8.50 millimeters, but preferably is between 5.50 and 7.00 millimeters. The top lens 300 features an optical aperture ranging from 3.0 millimeters to 7.0 millimeters, with a preferable optical aperture of 5.5 millimeters.

The mid lens 200 and/or the top lens 300 may serve multiple purposes depending on the specific embodiment and the specific nature of the problem to be solved. For example, the top lens 300 and/or the mid lens 200 may correct myopia, presbyopia, or astigmatism. The top lens 300 and/or the mid lens 200 may also be used to correct cosmetic defects in the eye. The top lens 300 and/or the mid lens 200 may also be tinted to protect the eye from ultraviolet rays, or blue light, or to reduce glare, or to change the color of the eye for cosmetic or other purposes. The top lens 300 and/or the mid lens 200, like the base lens 100, may also be constructed in a manner which allows the top lens 300 and/or the mid lens 200 to

absorb light in the ultraviolet wavelength portion of the light spectrum, for the purpose of achieving the same goals as mentioned above.

In an embodiment of the present invention, the top lens 300 and/or the mid lens 200 may be designed to change the lightgathering aspects of the eye to improve night vision. A lens with these characteristics has potential use for military applications, such as low light or telescopic use, or for underground workers, or in any other application where the patient desires reversibly enhanced night vision, or vision enhancement in a specific area of the spectrum. For example, athletes such as baseball players may desire amber-tinted lenses to improve their ability to perform the tasks critical to their sport, such as seeing the ball. Lenses designed for this purpose could be removed when the patient no longer desires the enhanced vision characteristic, for example when the military application is finished, or the athlete's season or career ends.

In another embodiment of the present invention, the top lens 300 and/or the mid lens 200 may be used to deliver pharmacological compounds, such as medicines, into the eye. The top lens 300 and/or the mid lens 200 in this embodiment feature a system for delivering a compound into the eye over a predetermined period of time. At the end of the predetermined time period, the surgeon removes the top lens 300 and/or the mid lens 200, and replaces the top lens 300 and/or 25 the mid lens 200 with a new lens for delivering a compound into the eye, if needed. In this way, the patient may conveniently receive delivery of a compound directly into the inner portions of the eye, while minimizing the risk to the patient, and simplifying the delivery of the compound. Because this 30 treatment does not require recurring action by the patient, the treatment avoids the problem of patient non-compliance, which is critically important to the treatment of chronic eye disorders, such as glaucoma, diabetes, and macular degeneration.

FIG. 14A illustrates a top view of the mid lens 200 of an embodiment of the present invention. The mid lens 200 includes one or more projections 210 extending horizontally from the body of the mid lens 200, preferably in the plane parallel to the edge of the mid lens 200, but optionally at any 40 angle from 150 to 180 degrees in either direction. Each projection 210 may extend outward from the lens ranging from 0.5 to 5.0 millimeters from the outer edge of the mid lens 200. Each projection 210 may also have varying lengths depending on the shape and number of projections. The projections 4 are illustrated in FIG. 14A as trapezoidal, but any shape which would accomplish the stated purpose of fitting into slot 110 of the flange 105 extending from the base lens 100, for example, rectangular, triangular, half-oval, notched, ridged, serrated, or any other suitable geometric shape, is considered 50 to be within the scope and pervue of the present invention. Additionally, any shape, indentation, marking, notching, or surface treatment of the flange 105, including, for example, ribbing, roughening, adding bumps, notches, and indentations, are considered to be within the scope and prevue of the 55 present invention. Likewise, the use of any adhesive material on the flange, for example, glues, Velcros, cements, resins, pastes, or any other adherent, is also considered to be within the scope and pervue of the present invention.

The mid lens 200 also comprises a side portion 250 which 60 extends upward, and terminates at a lip 225, as illustrated in FIG. 14B. The side portion 250 and lip 225 extend along the outer circumference of the mid lens 200, thereby defining a notch 230. Although the lip 225 is illustrated in FIG. 14B as having a relatively squared off end, the lip 225 may be configured to any suitable shape which does not prevent the formation of the notch 230, such as, for example, a rounded

10

end, an angled end, or a pointed end. Further, although not illustrated in FIG. 14B, the lip 225 may also optionally be surface treated to have at least one of bumps, ridges, bevels, serrated teeth, gouges, notches, impressions, recesses, or other such surface treatments that are suitable for use in a notch. Additionally, although the notch 230 is illustrated as substantially defining a right angle between the side portion 250 and the lip 225, the angle formed between the notch 230 and the lip 225 may range from 45 degrees to 135 degrees.

Prior to insertion into the eye, the top lens 300 (described further herein with respect to FIG. 15) engages the notch 225, such that a seal is formed between the notch 225 and the top lens 300, and which holds the mid lens 200 and the top lens 300 together as a single assembly. The top lens 300 includes a groove 320 defined in a surface of the top lens 300, and extends along the circumference of the outer periphery of the top lens 300. The groove 320 extends along the circumference of the top lens 300, except for the location of the compression slots 315, as shown in FIG. 15. Although four compression slots are illustrated here, embodiments with more compression slots or fewer compression slots are also considered to be within the scope and pervue of the invention. Groove 320 and a series of compression slots 315 allow easier fitting of the top lens 300 into the mid lens 200. In other embodiments, the groove 320 could be replaced with other slots or channels defined in the periphery of the lens, and the invention should not be considered to be limited to this specific embodiment.

The top lens 300 also includes one or more end notches 305. In FIG. 15, two end notches 305 are illustrated, but varying numbers of end notches, or no end notches at all, are considered to be within the scope of the invention. The end notches 305 are raised slightly from the surface of the top lens 300, and can be configured to be any one of notches, bumps, ridges, or indentations. The notches could also be of various shapes, sizes, and lengths. The top lens 300 is oriented so that, when the top lens 300 is inserted into the mid lens 200, as discussed below, the raised projections or notches 305 face the mid lens 200 or may also project away from the mid lens 200. The notches or projections 305 can provide directional and axial orientation for the top lens, similar to the axis orientation marks 85 of FIG. 5.

The surgeon performing the operation or the lens manufacturer assembles the mid lens 200 and the top lens 300 outside the eye to a predetermined axis orientation to correct the astigmatism, and then inserts the completed assembly into the eye as one folded piece. A side view of the completed assembly of the top lens 300 and the mid lens 200 is illustrated in FIG. 16. It is noted that in FIG. 16, the angles and sizes have been exaggerated in order to illustrate the relationship between the top lens 300 and the mid lens 200. It is also noted that, although in FIG. 16, the side portion of top lens 300 is flush with the side region 250 of the mid lens 200, and the bottom portion of top lens 300 is flush with the top portion of the mid lens 200, this fitting is not required for the assembly of the top lens 300 and mid lens 200. That is, embodiments in which the side portion of the top lens 300 is not flush with side region 250 of the mid lens are considered to be within the scope and pervue of the invention.

Once the base lens 100 has been inserted into and mounted within the eye, the surgeon inserts the top lens 300 and the mid lens 200 assembly into the base lens 100 by sliding a projection 210 into a slot 110 of a corresponding flange 105 of the base lens 100. When attaching the assembly of the top lens 300 and the mid lens 200 to the base lens 100, the surgeon does not need to visually see the individual pieces line up together. Instead, projection 210 is designed to slide into place with the slot 110. That is, the surgeon unfolds the

assembly of the top lens 300 and the mid lens 200, and then slides the assembly across the base lens 100 until a first projection 210 lines up with a first slot 110. Once a projection 210 lines up with a slot 110, the projection 210 catches in the slot 110, and the surgeon will feel the two pieces lock into 5 place. Once the first projection 210 is in place in the corresponding first slot 110, if more projections are present in the mid lens 200, then the surgeon adjusts the mid lens 200 and the top lens 300 until the other projection(s) 210 line up with the other slot(s) 105. Once all projections 210 have been 10 inserted into their corresponding slots 110, the assembly of the top lens 300 and the mid lens 200 is secured in the base lens 100, and the procedure is completed.

and the top lens 300 requires replacement, the surgeon may perform a disassembly procedure as discussed herein. First, a cannula containing visco elastic material would be introduced into the eye and positioned at the interface between the lens assembly (mid lens 200 and top lens 300) and the base lens 100. The injection of visco elastic causes the mid 200/top 20 300 lens assembly to elevate, thus disengaging the projections 210 from the slots 110 in the base lens 100. The original lens assembly would then be removed from the eye, and a new lens assembly placed into the eye and attached to the base lens 100 similar to as described above in the primary operation.

While the invention has been described in conjunction with specific embodiments therefor, it is evident that various changes and modifications may be made, and the equivalents substituted for elements thereof without departing from the true scope of the invention. In addition, many modifications 30 may be made to adapt a particular situation or material to the teachings of the invention without departing from the scope thereof. Therefore, it is intended that this invention not be limited to the particular embodiment disclosed herein, but will include all embodiments within the spirit and scope of the 35 disclosure.

For example, the mid lens 200 may also have additional spherical power ranging from -9.50 D to 9.50 D in 0.25 D increments, and may be either monofocal or multifocal. The top lens 200 may also be constructed from acrylic, silicone, or 40 any other material suitable for crafting a foldable intraocular lens. The mid lens has a plano-convex lens with a central thickness ranging from 0.1 to 0.3 millimeters, and a diameter ranging from 1.5 to 8.5 millimeters, preferably between 6.0 and 6.5 millimeters, and an optical clear aperture ranging 45 from 5.0 to 6.0 millimeters, preferably 5.5 mm. Similar to the base lens 100 and the top lens 300, the mid lens 200 may also be manufactured in a manner to allow absorption of light in the ultraviolet wavelength portion of the light spectrum, or other portions of the light spectrum for which it may be 50 clinically important to absorb light, such as the blue light portion.

Also, the mid lens 200 may have at least one bevel 210 formed along an outer edge thereof, allowing the mid lens 200 to fit into the opening 110 of the base lens 100. The mid lens 55 200 has a projection/notch 225, 230 that allows compression of the top lens 300 in order for the top lens 300 to fit inside the projection/notch 225, 230 of the mid lens 200. Prior to insertion into the eye, the surgeon or manufacturer places the top lens 300 into the mid lens 200, and seals the top lens under the 60 notch 225 around the entire circumference of the mid lens. The assembly is then ready for insertion into the eye of the patient.

The three piece system (i.e. the base lens 100, the mid lens 200, and the top lens 300) described herein has a spherical 65 power range of -20.00 D to +40.00 D and accuracy of +/-0.25 D. The three piece system has an adjustable cylindrical power

12

of 5.00 D, and adjustable spherical power of +/-9.00 D. Its maximum central thickness is 1.88 millimeters, but could be as thick as 4.0 millimeters. The optical element diameter ranges from 1.00 millimeters to 8.00 millimeters. The optical aperture ranges from 3.0 to 7.0 millimeters, with an optimal optical aperture of 5.5 millimeters.

Any of the base, top, and/or mid lens components may be coated with chemicals to decrease their cellular reactivity, such as heparin or other surface passivation techniques to prevent building of cellular debris at the optical interface. Moreover, any of the lens components may be configured with a multifocal corrective component of any of several varieties: derefractive or refractive, bull's eye or aspheric, depending upon the desired optical characteristics. Additionally, extra components beyond the basic base, top, and mid components may be added to help with optical aberrations or other focusing refinements. In an embodiment of the present invention, additional top lenses may be added to the base lens 100, and attached in the same manner as the assembly of the top 300 and the mid lens 200 described above.

In another embodiment of the present invention, a telescopic lens can be introduced into the lens system for the treatment of macular degeneration. If the base lens 105 illustrated in FIG. 13 is used, then the surgeon can cut the attachment points 140 while the lens is in the eye, and remove the central optic 150 of the base lens 105. The surgeon can then implant a telescopic assembly, for example a Lipschitz telescopic assembly, in place of the optic portion of the base lens 105, to allow optical correction for macular degeneration.

By using specific predetermined combinations of lens powers for each of the three components, it is possible to achieve a large variety of possible corrective power while requiring only a minimum number of different lenses to be manufactured. By placing small degrees of spherical construction in each of the three optical components, a surgeon can, from a very limited inventory of lenses, construct all of the corrections needed to achieve optical powers from –20.00 D to +40.00 D of spherical correction, and from 0.0 to 5.0 D of cylindrical correction in any axis, all in standard 0.25 D steps.

Optical aberrations and abnormalities present after implantation of the intraocular lens are identified by measuring the optical system using, for example, wave front technology. A surface modifier may be used to modify either a surface of the eye itself, or a component of the intraocular lens system. If a component requires modification or replacement, the surgeon can remove the component, alter the component or replace it with another, and reinsert the component through the same wound which was used to implant the lens. This process is described more fully in U.S. Pat. No. 6,413,276, "Modified Intraocular Lens and Method of Correcting Optical Aberrations Therein," by the same inventor.

What is claimed is:

- 1. A multi-component intraocular lens implantable in an optical system of a human eye, comprising:
 - a base lens having an anterior surface configured to face a front of the human eye, a posterior surface on an opposite side of the base lens relative to the anterior surface and configured to face a back of the human eye, a circumferential side surface connecting the anterior and posterior surfaces, and at least one projection extending away from the circumferential side surface and configured for securing the base lens within tissue of the human eye, the base lens being manufactured from a first foldable material and including at least one flange disposed on and extending orthogonally away from the anterior surface of the base lens toward the front of the

human eye, the at least one flange including an aperture defined therein, the aperture being located only above the anterior surface of the base lens; and

- an optical assembly which selectively engages the anterior surface of the base lens, the optical assembly being 5 manufactured from a second foldable material.
- 2. The intraocular lens of claim 1, wherein the foldable optical assembly comprises:
 - at least one tab extending therefrom, the tab configured to engage the aperture of the at least one flange of the base 10 lens.
- 3. The intraocular lens of claim 2, wherein the tab is surface treated selected from the group of: notched, slotted, grooved, ridged, roughened, ribbed, gouged, striated, rifled, sulcated, corrugated, crimped, or canaliculated.
- 4. The intraocular lens of claim 1, wherein the foldable optical assembly comprises:

a top lens; and

a mid lens that removably engages the top lens.

- 5. The intraocular lens of claim 4, wherein the mid lens comprises an L-shaped lip extending upward and away from a planar surface of the top lens, wherein a notch is defined by the lip and the planar surface.
- 6. The intraocular lens of claim 5, wherein the top lens is 25 secured in the mid lens by the lip.
- 7. The intraocular lens of claim 5, wherein at least one side of the lip is beveled.
- 8. The intraocular lens of claim 7, wherein the notch engages at least an outer perimeter of the top lens.
- 9. The intraocular lens of claim 4, wherein at least one tab extends from the mid lens, the at least one tab configured to engage the aperture defined in at least one flange extending from the base lens.
- 10. The intraocular lens of claim 4, wherein the top or mid lens is constructed with a predetermined cylinder and diopter value for correcting astigmatism.

14

- 11. The intraocular lens of claim 4, wherein the top or mid lens includes a coating capable of blocking or absorbing a specific light wavelength or range of wavelengths.
- 12. The intraocular lens of claim 4, wherein the top or mid lens is configured to deliver a pharmaceutical compound into an inner portion of the human eye.
- 13. The intraocular lens of claim 4, wherein the top or mid lens is provided with a coating which enhances the human eye's ability to see particular area of a light spectrum.
- 14. The intraocular lens of claim 4, wherein the top lens is provided with a coating which enhances the human eye's ability to see at night.
- 15. The intraocular lens of claim 4, wherein at least one of the mid lens and the top lens has at least one vision corrective component.
- 16. The intraocular lens of claim 1, wherein the aperture has a shape selected from the group of: an ellipse, an oval, a trapezoid, a rounded rectangle, a parallelogram, a pentagon, hexagon, and an octagon.
- 17. The intraocular lens of claim 1, wherein the base lens has at least one vision corrective component.
 - 18. The intraocular lens of claim 1, wherein the first foldable material is the same as the second foldable material.
 - 19. The intraocular lens of claim 1, wherein the first foldable material is different from the second foldable material.
 - 20. The intraocular lens of claim 1, wherein the base lens includes a removable optic portion defined by at least one breakable attachment point.
- 21. The intraocular lens of claim 20, wherein the base lens further includes an annular housing joined to the removable optic portion by the at least one breakable attachment point.
- 22. The intraocular lens of claim 21, wherein a telescopic lens assembly is inserted through the annular housing and retained therein by the at least one flange of the base lens in place of the removable optic portion once the removable optic portion is removed by cutting the at least one breakable attachment point.

* * * *